Your search matched 48 results
With funding from Google, Stanford, and venture capital giants Sequoia and Andreessen Horowitz, seven-year-old Zipline has already revolutionized health care in Rwanda.
A landmark approval by the FDA will put the first marijuana-derived prescription drug behind pharmacy counters this fall.
Nonprofit hospital system Partners HealthCare has unveiled a joint venture with Circulation, an on-demand rideshare service, through which Medicare patients receive free rides to their doctor’s offices in non-emergencies.
The State Supreme Court just resolved a 10-year battle between the Cleveland Clinic and a former patient, retired U.S.
Beginning with its acquisition of PillPack, Amazon’s grand entrance into healthcare continues with its partnership with J.P.
Complications from drug interactions can present patients with whole new afflictions.
The growing appeal of orphan drugs to manufacturers isn’t a groundbreaking story, but a new report identifies some head-spinning facts behind the focal shift from blockbuster to rare-disease drugs.
Holistic healthcare brand Otsuka Pharmaceutical has announced a promising partnership with Science 37, the trailblazing startup out of MIT that’s transforming clinical trials for everyone.
A new Deloitte report explores the near-future of blockchain: how seriously the world’s top executives, including many in healthcare, regard the emerging technology and how soon they might invest in it.
Advantia Health, a leading-edge medical company committed to empowering women with integrated health care services, announced a new partnership with Elligo Health Research, which will offer Advantia’s clients access to a whole new realm of resources, through clinical trials.
A recent proposal by the U.S.
To retail behemoths, the health care realm is growing irresistible.
After taking some major leaps into healthcare, Google has begun solidifying its foothold in the space by appointing Dr.
In a telling new study, pre- and post-surgical efforts by pharmacists yielded staggering effects on patient opioid use.
Pharmaceutical giant Roche’s new app for people with multiple sclerosis (MS) revolutionizes how doctors care for patients with the disease.
Pfizer and Novartis have been independently developing therapies for nonalcoholic steatohepatitis (NASH), and they’re now set to join forces to yield a combination therapy for the fatty liver disease linked closely with metabolic disorders.
Forecasting next year’s biggest shifts within the healthcare landscape, Syneos Health has released 2019 Health Trend Ten, available for download now, which explicates ten of the trends that will redefine healthcare globally.
Amazon Web Services (AWS) has unveiled new machine-learning tools reflecting—and beginning to tackle—some of the greatest challenges facing modern medicine.
GlaxoSmithKline announced that it will acquire Waltham, Massachusetts-based drug company Tesaro, which develops novel cancer treatments, for $5.1 billion cash.
Tilray, a medical-cannabis producer, has established a new partnership with pharmaceutical giant Novartis, affording the former sales and distribution channels in tens of new countries.
In the first half of this new year, the United States FDA will incentivize many pharmaceutical brands to make their biggest prescription drugs available over the counter.
While the term “micro-influencer” may still sound to you like some flippant, gen-Z farce, the side hustle cum way of life just scored serious validation.
As the use of artificial intelligence in R&D continues to rise, Novartis takes it even further, equipping its reps with AI that suggests the perfect things to talk about with HCPs.
Not your typical geotag for pharmaceutical innovation, Jackson Hole and its most prominent biologist, Paul Cox, may turn decades’ and billions of dollars’ worth of Alzheimer’s research on its head.
Digital health company Peerwell created an app to prepare patients for surgery and, in turn, reduce the amount of time they spend in the hospital.
At this year’s Digital Medicine & MedTech Showcase (part of Biotech Showcase), a panel of digital therapeutics (DTx) experts illuminated the status and future of their work, moderated by Syneos Health Commercial Solutions Chief Strategy Officer, Baba Shetty.
F.D.A. | Blog
An expert panel that advises U.S. federal regulatory authorities has recommended approval of Esketamine, Johnson & Johnson’s brand-new treatment for depression.
Digital therapeutics, or DTx, are distinct from digital health products, and are driven by software programs that can be prescribed to prevent, manage, or treat a medical disorder or disease, as stated by the Digital Therapeutics Alliance.
According to the U.S.